



MAIL STOP - PCT  
Docket No.: 27598U

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: PALMER, et al.

Art Unit: XX

Appl. No.: 10/591,957

Examiner: XX

Appl. Filing Date: September 8, 2006

Intl. Appl. No.: PCT/EP2005/051211

Intl. Appl. Filing Date: March 16, 2005

For: **TRICYCLIC IMIDAZOPYRIDINES**

TRANSMITTAL LETTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1. Information Disclosure Statement; and
2. PTO Form-1449 with 27 references cited, and copies of 26 of the 27 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

November 6, 2006

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

Le

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor: PALMER, et al.

Art Unit: XX

Appl. No.: 10/591,957

Examiner: XX

Appl. Filing Date: September 8, 2006

Intl. Appl. No.: PCT/EP2005/051211

Intl. Appl. Filing Date: March 16, 2005

For: **TRICYCLIC IMIDAZOPYRIDINES**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a.  The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b.  The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.  
The enclosed statement is accompanied by [check one]:  
 i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or  
 ii. a check in the amount required by 37 C.F.R. 1.17(p).

c.  The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.  
 Certification report(e) below; and  
 a check in the amount as required by 1.17(p).

d.  The enclosed statement is being filed pursuant to 37

C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b) (i) or box (c) is checked.]

[ ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,  
or

[ ] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[ ] Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XX] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

[ ] Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents


MAIL STOP - PCT  
Docket No.: 27598U

have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

November 6, 2006

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

Le

PTO FORM-144

PATENT TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

Inventor: PALMER, et al.

|   |  |              |
|---|--|--------------|
| Appl. No.:<br>10/591,957                | Intl. Appl. No:<br>PCT/EP2005/051211       | Art Unit: XX |
| Appl. Filing Date:<br>September 8, 2006 | Intl. Appl. Filing Date:<br>March 16, 2005 | Examiner: XX |

## U. S. PATENT DOCUMENTS

| Exam.<br>Initial |    | Document No. | Issue/Public. Date | Inventor    | Filed Date |
|------------------|----|--------------|--------------------|-------------|------------|
|                  | A1 | 4,468,400    | 8/28/1984          | Gold et al. | 12/20/1982 |

## FOREIGN PATENT DOCUMENTS

| Exam.<br>Initial |     | Document No.   | Public. Date | Country | Translation |
|------------------|-----|----------------|--------------|---------|-------------|
|                  | A2  | 01/72756 A1    | 10/4/2001    | WO      | N/A         |
|                  | A3  | 01/72755 A1    | 10/4/2001    | WO      | N/A         |
|                  | A4  | 01/72754 A1    | 10/4/2001    | WO      | N/A         |
|                  | A5  | 00/63211 A1    | 10/26/2000   | WO      | N/A         |
|                  | A6  | 00/50037 A1    | 8/31/2000    | WO      | N/A         |
|                  | A7  | 00/26217 A1    | 5/11/2000    | WO      | N/A         |
|                  | A8  | 00/17200 A1    | 3/30/2000    | WO      | N/A         |
|                  | A9  | 01/72757 A1    | 10/4/2001    | WO      | N/A         |
|                  | A10 | 02/069968 A1   | 9/12/2002    | WO      | N/A         |
|                  | A11 | 02/34749 A1    | 5/2/2002     | WO      | N/A         |
|                  | A12 | 03/016310 A1   | 2/27/2003    | WO      | N/A         |
|                  | A13 | 03/014123 A1   | 2/20/2003    | WO      | N/A         |
|                  | A14 | 03/068774 A1   | 8/21/2003    | WO      | N/A         |
|                  | A15 | 03/014120 A1   | 2/20/2003    | WO      | N/A         |
|                  | A16 | 03/091253 A1   | 11/6/2003    | WO      | N/A         |
|                  | A17 | 2005/058894 A1 | 6/30/2005    | WO      | N/A         |
|                  | A18 | 95/27714 A1    | 10/19/1995   | WO      | N/A         |
|                  | A19 | 2005/058325 A1 | 6/30/2005    | WO      | N/A         |
|                  | A20 | 98/54188 A1    | 12/3/1998    | WO      | N/A         |
|                  | A21 | 2005/077949 A1 | 8/25/2005    | WO      | N/A         |
|                  | A22 | 98/42707 A1    | 10/1/1998    | WO      | N/A         |

## OTHER

| Exam.<br>Initial | (Including Author, Title, Date, Pertinent Pages, etc.) |   |
|------------------|--|---|
|                  | A23  | Kaminski, J.J., et al., "Antiulcer Agents. 5. Inhibition of Gastric H <sup>+</sup> /K <sup>+</sup> -ATPase by Substituted Imidazo[1,2-a]pyridines and Related Analogues and Its Implication in Modeling the High Affinity Potassium Ion Binding Site of the Gastric Proton Pump Enzyme", <u>J. Med. Chem.</u> , Vol. 34, pg. 533-541, (1991).   |
|                  | A24  | Kaminski, J.J., et al., "Antiulcer Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidazo[1,2-a]pyridines", <u>J. Med. Chem.</u> , Vol. 28, pg. 876-892, (1985).   |
|                  | A25  | Kaminski, J.J., et al., "Antiulcer Agents. 4. Conformational Considerations and the Antiulcer Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogues", <u>J. Med. Chem.</u> , Vol. 32, pg. 1686-1700, (1989).  |
|                  | A26  | Middleton, D.A., et al., "The conformation of an inhibitor bound to the gastric proton pump", <u>FEBS Letters</u> , Vol. 410, pg. 269-274, (1997).  |
|                  | A27  | Kaminski, J.J., et al., "Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogues Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies", <u>J. Med. Chem.</u> , Vol. 40, pg. 427-436, (1997). |

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.